C-reactive protein modifies lipoprotein(a)-related risk for coronary heart disease : the BiomarCaRE project
© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com..
BACKGROUND AND AIMS: Recent investigations have suggested an interdependence of lipoprotein(a) [Lp(a)]-related risk for cardiovascular disease with background inflammatory burden. The aim the present analysis was to investigate whether high-sensitive C-reactive protein (hsCRP) modulates the association between Lp(a) and coronary heart disease (CHD) in the general population.
METHODS: Data from 71 678 participants from 8 European prospective population-based cohort studies were used (65 661 without/6017 with established CHD at baseline; median follow-up 9.8/13.8 years, respectively). Fine and Gray competing risk-adjusted models were calculated according to accompanying hsCRP concentration (<2 and ≥2 mg/L).
RESULTS: Among CHD-free individuals, increased Lp(a) levels were associated with incident CHD irrespective of hsCRP concentration: fully adjusted sub-distribution hazard ratios [sHRs (95% confidence interval)] for the highest vs. lowest fifth of Lp(a) distribution were 1.45 (1.23-1.72) and 1.48 (1.23-1.78) for a hsCRP group of <2 and ≥2 mg/L, respectively, with no interaction found between these two biomarkers on CHD risk (Pinteraction = 0.82). In those with established CHD, similar associations were seen only among individuals with hsCRP ≥ 2 mg/L [1.34 (1.03-1.76)], whereas among participants with a hsCRP concentration <2 mg/L, there was no clear association between Lp(a) and future CHD events [1.29 (0.98-1.71)] (highest vs. lowest fifth, fully adjusted models; Pinteraction = 0.024).
CONCLUSIONS: While among CHD-free individuals Lp(a) was significantly associated with incident CHD regardless of hsCRP, in participants with CHD at baseline, Lp(a) was related to recurrent CHD events only in those with residual inflammatory risk. These findings might guide adequate selection of high-risk patients for forthcoming Lp(a)-targeting compounds.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:45 |
|---|---|
| Enthalten in: |
European heart journal - 45(2024), 12 vom: 27. März, Seite 1043-1054 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
9007-41-4 |
|---|
| Anmerkungen: |
Date Completed 29.03.2024 Date Revised 29.03.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/eurheartj/ehad867 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367308843 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367308843 | ||
| 003 | DE-627 | ||
| 005 | 20240330000810.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240119s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/eurheartj/ehad867 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1355.xml |
| 035 | |a (DE-627)NLM367308843 | ||
| 035 | |a (NLM)38240386 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Arnold, Natalie |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a C-reactive protein modifies lipoprotein(a)-related risk for coronary heart disease |b the BiomarCaRE project |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.03.2024 | ||
| 500 | |a Date Revised 29.03.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com. | ||
| 520 | |a BACKGROUND AND AIMS: Recent investigations have suggested an interdependence of lipoprotein(a) [Lp(a)]-related risk for cardiovascular disease with background inflammatory burden. The aim the present analysis was to investigate whether high-sensitive C-reactive protein (hsCRP) modulates the association between Lp(a) and coronary heart disease (CHD) in the general population | ||
| 520 | |a METHODS: Data from 71 678 participants from 8 European prospective population-based cohort studies were used (65 661 without/6017 with established CHD at baseline; median follow-up 9.8/13.8 years, respectively). Fine and Gray competing risk-adjusted models were calculated according to accompanying hsCRP concentration (<2 and ≥2 mg/L) | ||
| 520 | |a RESULTS: Among CHD-free individuals, increased Lp(a) levels were associated with incident CHD irrespective of hsCRP concentration: fully adjusted sub-distribution hazard ratios [sHRs (95% confidence interval)] for the highest vs. lowest fifth of Lp(a) distribution were 1.45 (1.23-1.72) and 1.48 (1.23-1.78) for a hsCRP group of <2 and ≥2 mg/L, respectively, with no interaction found between these two biomarkers on CHD risk (Pinteraction = 0.82). In those with established CHD, similar associations were seen only among individuals with hsCRP ≥ 2 mg/L [1.34 (1.03-1.76)], whereas among participants with a hsCRP concentration <2 mg/L, there was no clear association between Lp(a) and future CHD events [1.29 (0.98-1.71)] (highest vs. lowest fifth, fully adjusted models; Pinteraction = 0.024) | ||
| 520 | |a CONCLUSIONS: While among CHD-free individuals Lp(a) was significantly associated with incident CHD regardless of hsCRP, in participants with CHD at baseline, Lp(a) was related to recurrent CHD events only in those with residual inflammatory risk. These findings might guide adequate selection of high-risk patients for forthcoming Lp(a)-targeting compounds | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Coronary heart disease | |
| 650 | 4 | |a Epidemiology | |
| 650 | 4 | |a General population | |
| 650 | 4 | |a High-sensitive C-reactive protein | |
| 650 | 4 | |a Lipoprotein(a) | |
| 650 | 7 | |a C-Reactive Protein |2 NLM | |
| 650 | 7 | |a 9007-41-4 |2 NLM | |
| 650 | 7 | |a Lipoprotein(a) |2 NLM | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 700 | 1 | |a Blaum, Christopher |e verfasserin |4 aut | |
| 700 | 1 | |a Goßling, Alina |e verfasserin |4 aut | |
| 700 | 1 | |a Brunner, Fabian J |e verfasserin |4 aut | |
| 700 | 1 | |a Bay, Benjamin |e verfasserin |4 aut | |
| 700 | 1 | |a Ferrario, Marco M |e verfasserin |4 aut | |
| 700 | 1 | |a Brambilla, Paolo |e verfasserin |4 aut | |
| 700 | 1 | |a Cesana, Giancarlo |e verfasserin |4 aut | |
| 700 | 1 | |a Leoni, Valerio |e verfasserin |4 aut | |
| 700 | 1 | |a Palmieri, Luigi |e verfasserin |4 aut | |
| 700 | 1 | |a Donfrancesco, Chiara |e verfasserin |4 aut | |
| 700 | 1 | |a Padró, Teresa |e verfasserin |4 aut | |
| 700 | 1 | |a Andersson, Jonas |e verfasserin |4 aut | |
| 700 | 1 | |a Jousilahti, Pekka |e verfasserin |4 aut | |
| 700 | 1 | |a Ojeda, Francisco |e verfasserin |4 aut | |
| 700 | 1 | |a Zeller, Tanja |e verfasserin |4 aut | |
| 700 | 1 | |a Linneberg, Allan |e verfasserin |4 aut | |
| 700 | 1 | |a Söderberg, Stefan |e verfasserin |4 aut | |
| 700 | 1 | |a Iacoviello, Licia |e verfasserin |4 aut | |
| 700 | 1 | |a Gianfagna, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Sans, Susana |e verfasserin |4 aut | |
| 700 | 1 | |a Veronesi, Giovanni |e verfasserin |4 aut | |
| 700 | 1 | |a Thorand, Barbara |e verfasserin |4 aut | |
| 700 | 1 | |a Peters, Annette |e verfasserin |4 aut | |
| 700 | 1 | |a Tunstall-Pedoe, Hugh |e verfasserin |4 aut | |
| 700 | 1 | |a Kee, Frank |e verfasserin |4 aut | |
| 700 | 1 | |a Salomaa, Veikko |e verfasserin |4 aut | |
| 700 | 1 | |a Schnabel, Renate B |e verfasserin |4 aut | |
| 700 | 1 | |a Kuulasmaa, Kari |e verfasserin |4 aut | |
| 700 | 1 | |a Blankenberg, Stefan |e verfasserin |4 aut | |
| 700 | 1 | |a Koenig, Wolfgang |e verfasserin |4 aut | |
| 700 | 1 | |a Waldeyer, Christoph |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European heart journal |d 1983 |g 45(2024), 12 vom: 27. März, Seite 1043-1054 |w (DE-627)NLM012617253 |x 1522-9645 |7 nnns |
| 773 | 1 | 8 | |g volume:45 |g year:2024 |g number:12 |g day:27 |g month:03 |g pages:1043-1054 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/eurheartj/ehad867 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 45 |j 2024 |e 12 |b 27 |c 03 |h 1043-1054 | ||